Rauch-Kröhnert, Ursula
Puccini, Marianna
Placzek, Marius
Beyer-Westendorf, Jan
Jakobs, Kai
Friebel, Julian
Hein, Selina
Seidel, Mirko
Pieske, Burkert
Massberg, Steffen
Witzenrath, Martin
Zeiher, Andreas
Friede, Tim
Anker, Stefan D.
Landmesser, Ulf
Funding for this research was provided by:
Bayer
DZHK
Charité - Universitätsmedizin Berlin
Article History
Received: 1 April 2023
Accepted: 30 May 2023
First Online: 5 July 2023
Declarations
:
: The authors received a research grant from Bayer that was used together with the Funding of DZHK for conducting the study. S.D. Anker received grants and personal fees from Vifor and Abbott Vascular, and personal fees for consultancies, trial committee work and/or lectures from Actimed, Amgen, Astra Zeneca, Bayer, Boehringer Ingelheim, Bioventrix, Brahms, Cardiac Dimensions, Cardior, Cordio, CVRx, Cytokinetics, Edwards, Farraday Pharmaceuticals, GSK, HeartKinetics, Impulse Dynamics, Novartis, Occlutech, Pfizer, Repairon, Sensible Medical, Servier, Vectorious, and V-Wave. Named co-inventor of two patent applications regarding MR-proANP (DE 102007010834 and DE 102007022367), but he does not benefit personally from the related issued patents.
: The clinical trial was approved according to local regulatory requirements by the lead ethical committee and was performed according to the Declaration of Helsinki. All participants were included in the study after giving written consent.